Skip to content

Not medical advice. Talk to your provider before using any peptide. Full disclaimer

Syn-Ake peptide icon, one bubble per amino acidSyn-Ake3 residues (approx.)APKEach bubble = one amino acid. Size = residue mass. Color = chemical class.Uses closest standard amino acids for non-standard residues.

Syn-Ake

Anti-AgingResearch
Unknown half-life·Topical·12w on / 2w off

Also known as: Tripeptide-3, SYN-AKE, Snake Venom Peptide

In cultured muscle cells, a single tripeptide cut contraction frequency by 82% in two hours. Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate, CAS 823202-99-9) is a synthetic peptide modeled after Waglerin-1 from Temple Pit Viper venom. It blocks the postsynaptic nicotinic acetylcholine receptor, relaxing facial muscles topically instead of through injection. No independent placebo-controlled RCT isolating Syn-Ake in humans has been published yet. The manufacturer's own 45-subject study found up to 52% forehead wrinkle depth reduction at 28 days using a 4% cream. Skincare formulators and anti-aging protocol builders use it as a non-invasive complement to botulinum toxin, often stacked with SNAP-8 for dual neuromuscular coverage.

What Is Syn-Ake?

Syn-Ake (Dipeptide Diaminobutyroyl Benzylamide Diacetate, Tripeptide-3, CAS 823202-99-9) is a synthetic tripeptide built to mimic Waglerin-1, a paralytic peptide from the Temple Pit Viper (Tropidolaemus wagleri). The manufacturer's own 45-subject study reported 52% forehead wrinkle depth reduction at 28 days with 4% cream. No actual snake venom is involved. DSM-Firmenich synthesizes it chemically, and the compound is vegan-compatible.

The mechanism is specific. Syn-Ake binds to the epsilon subunit of the muscular nicotinic acetylcholine receptor at the neuromuscular junction. That binding blocks acetylcholine from triggering muscle contraction. The result: localized relaxation of the frontalis, orbicularis oculi, and corrugator supercilii, the muscles responsible for forehead lines, crow's feet, and frown lines. Unlike botulinum toxin, this binding is fully reversible. Stop applying it and muscle function returns within one to two weeks.

The skincare formulator community has adopted a standard stack: 4% Syn-Ake plus 10% SNAP-8 in a hyaluronic acid serum base, applied twice daily. SNAP-8 blocks acetylcholine release presynaptically while Syn-Ake blocks the receptor postsynaptically. The combination covers both sides of the neuromuscular junction.

Research status is honest: no independent double-blind placebo-controlled RCT isolating Syn-Ake as a single active exists. The most-cited human study (Trookman 2009)[1] tested a multi-ingredient product funded by SkinMedica. Gok and colleagues confirmed the mechanism and safety profile through in silico and in vitro work [2]. Community experience across formulator forums and skincare subreddits is consistent: effects are real but more modest than Botox, landing around 20 to 30% visible improvement compared to Botox's 80 to 95%.

How Syn-Ake Works

Syn-Ake is a competitive antagonist of the muscular nicotinic acetylcholine receptor (mnAChR). The tripeptide targets the epsilon subunit of that receptor, sitting in the same binding pocket where acetylcholine normally docks.

When Syn-Ake occupies the site, acetylcholine can't trigger sodium ion channel opening. Without sodium influx, the motor endplate doesn't depolarize. Without depolarization, excitation-contraction coupling fails. The muscle relaxes.

This differs from botulinum toxin in a key way. Botox irreversibly cleaves SNARE complex proteins on the presynaptic side, stopping acetylcholine vesicle release entirely. Syn-Ake works on the opposite side of the synapse, and its binding is reversible. Once the peptide dissociates from the receptor, normal contraction resumes. That reversibility is both a safety feature and a limitation; the relaxation requires continuous topical application to maintain.

In cultured muscle cells, 0.025% Syn-Ake reduced contraction frequency by 36% within one minute and 82% within two hours. Topical onset through intact skin is slower because the peptide must cross the stratum corneum first. At 495.58 Da, Syn-Ake falls just below the 500 Da skin penetration threshold, enabling passive transcorneal diffusion without lipid conjugation.

Gok and colleagues [2] identified secondary binding targets through in silico modeling: SIRT1 (a sirtuin deacetylase in cellular longevity pathways) at -9.32 kcal/mol and matrix metalloproteinases MMP-1, MMP-8, and MMP-13. These interactions suggest possible collagen degradation inhibition beyond the primary neuromuscular effect. The peptide also scavenges free radicals in a concentration-dependent DPPH assay.

Syn-Ake Benefits

  • Syn-Ake benefits center on non-invasive neuromuscular relaxation of facial muscles and topical wrinkle reduction.
  • Up to 52% forehead wrinkle depth reduction at 28 days in a manufacturer-sponsored 45-subject human study using 4% cream.
  • 82% reduction in muscle cell contraction frequency within two hours at 0.025% concentration in cultured cells, confirmed by independent in vitro testing.
  • Non-invasive topical alternative to botulinum toxin injections. No needles, no downtime, no appointment required.
  • Complementary stacking with SNAP-8 (presynaptic SNARE inhibition plus postsynaptic receptor blockade) creates the most complete topical neuromuscular coverage available. The 4% Syn-Ake plus 10% SNAP-8 combination is the benchmark protocol in formulator communities.
  • Fully reversible mechanism. No permanent alteration of neuromuscular function; muscle contraction returns to baseline within one to two weeks of stopping.
  • Concentration-dependent antioxidant activity confirmed through DPPH radical scavenging assays and strong in silico binding to SIRT1 (-9.32 kcal/mol) and MMP-13 (Gok 2024)[2].

Syn-Ake: Science vs Community Consensus

Partially Aligned
Scientific Evidence
Weak
Based on 7 key studies·Research only

In vitro evidence for neuromuscular mechanism is strong (82% contraction reduction at 2h, 0.025% concentration, cultured muscle cells).

Dosing studied: 4% w/v topical, twice daily for ≥28 days (12 weeks for full assessment)
Read the evidence (key study, limitations)

Manufacturer-sponsored 45-subject human study shows 52% forehead wrinkle depth reduction at 28 days (4% cream). No independent, placebo-controlled RCT isolating Syn-Ake contribution in humans exists. The most-cited "clinical" study (Trookman 2009)[1] is industry-funded and tested a multi-ingredient product: efficacy cannot be attributed to Syn-Ake alone. A 2024 nanoemulsion study (PMC11053593) confirmed sebum/pore benefits at 0.012%: a different clinical endpoint. Overall: compelling mechanism, weak isolated human evidence.

Key Study

DSM-Firmenich manufacturer study: 45 healthy subjects, 4% Syn-Ake forehead cream, up to 52% wrinkle depth reduction at 28 days. Gok et al. 2024 (PMID 37349941): in silico + in vitro anti-aging activity, SIRT1 binding (−9.32 kcal/mol), MMP-13 inhibition, genotoxicity-favorable. McArdle et al. 1999 (PMID 10087048): Waglerin-1, the viper peptide Syn-Ake mimics, selectively blocks the epsilon-subunit form of the muscle nicotinic receptor in mice (Syn-Ake itself not tested).

Limitations

Primary efficacy study is manufacturer-funded and unpublished in peer review. Trookman 2009 (the most-cited human study) tested a multi-ingredient product: cannot isolate Syn-Ake contribution. No independent double-blind placebo-controlled RCT of Syn-Ake as a single active. Nanoemulsion 2024 study tested 0.012% (far below clinical 4%) for a different endpoint (sebum/pore size). No long-term safety or efficacy data (>12 weeks). Skin penetration depth at clinically relevant dermis levels unconfirmed.

Community Experience
Moderate
3.5/5
Based on niche: low Reddit volume (r/SkincareAddiction, r/DIYBeauty, r/30PlusSkinCare)

Valued by the skincare formulator and DIY community as a non-invasive topical Botox alternative.

Community dosing: 4% Syn-Ake + 10% SNAP-8 in HA serum base, twice daily, 12 weeks
Read the reports (what users report 5, common issues 5)

Results accepted as more modest than Botox; used as a complement or maintenance tool rather than a replacement. SNAP-8 combination at 4% Syn-Ake + 10% SNAP-8 is the benchmark stack. Skepticism centers on manufacturer-funded evidence and the full reversibility of effects.

What users report (5)
  • Non-invasive topical application: no needles, no downtime
  • Dual-mechanism stack with SNAP-8 (pre + postsynaptic neuromuscular inhibition) is well-tolerated and widely used
  • Well-tolerated with no systemic effects; high safety tolerance even at 7% in commercial products
  • Visible softening of expression lines (forehead, crow's feet) with consistent 4-week use in responders
  • Reversible mechanism perceived as a safety feature: no permanent alteration of muscle function
Common issues (5)
  • Results not comparable to Botox (community estimates ~20–30% visible improvement vs. Botox's 80–95%)
  • Full reversal within 1–2 weeks of stopping: no lasting structural benefit
  • Primary clinical evidence is manufacturer-sponsored; "snake venom serum" marketing drives skepticism
  • DIY formulators frequently under-concentrate (1% solutions); effective threshold is 3–4%
  • Applying post-chemical peel causes unpredictable absorption and potential irritation
Partially Aligned

Both science and community accept the postsynaptic mnAChR mechanism and 4% as the benchmark concentration. Science notes the absence of an independent isolated RCT; community accepts this gap and uses the product empirically, calibrating expectations below Botox. Disagreement is on magnitude of evidence, not mechanism or practical use.

Syn-Ake Dosage Guide

CommunityCosmeceutical industry standard concentrations
LevelDoseFrequency
Beginner2 mgDaily
Moderate4 mg2x Daily
Aggressive6 mg2x Daily
Note:

Syn-Ake is a topical peptide. No reconstitution, no bacteriostatic water, no syringes. You're working with serums and creams, not vials.

The most common mistake: using a product that says "contains Syn-Ake" without listing the actual percentage. Below 3%, efficacy drops off. The manufacturer's clinical data used 4%. A finished serum with a labeled 7% concentration is the usual reference product.

For DIY formulators working with raw powder (CAS 823202-99-9): dissolve in a hyaluronic acid serum base. 4 mg per 100 mg of final product gives you 4% w/w. That 200 mg supply makes roughly 5 g of 4% serum, enough for about a month of twice-daily facial application.

Apply to clean, dry skin. Not damp. Dampness changes absorption kinetics. Wait two to three minutes before layering moisturizer or SPF. Don't apply within 48 hours of a chemical peel. Store finished serums at 2 to 8 degrees Celsius and use within 6 months of opening.

Cycling Protocol

On Period
12 weeks
Off Period
2 weeks

Apply twice daily for 12 weeks to achieve full wrinkle-reducing effect. Manufacturer studies report significant results at 28 days, with continued improvement through 12 weeks. A 2-week break is optional: no receptor desensitization or tachyphylaxis has been reported with continuous use. The reversible competitive binding mechanism means effects diminish gradually over 1-2 weeks after discontinuation as receptor occupancy decreases. Long-term continuous use is commonly practiced in cosmeceutical regimens.

Calculate your Syn-Ake dose
Dosing tiers, timing, and cycle length

Or use the universal Peptide Calculator for any peptide.

Syn-Ake Protocols by Goal

beginnerCommunity12 weeks active; continuous use common for maintenance
Tolerance establishment
Wk 1–2
1–2% w/v concentration · Once daily (PM) · Topical
Step-up to clinical concentration
Wk 3–12
3–4% w/v concentration · Twice daily (AM + PM) · Topical

Expected: Gradual softening of forehead and periorbital expression lines by week 4–6 in responders; peak effect at weeks 8–12. Non-responders apparent by week 8. Manufacturer data: up to 52% wrinkle depth reduction at 4% over 28 days.

Monitor: Photograph expression lines in consistent lighting at baseline, week 4, and week 12. Discontinue if contact dermatitis develops. Verify product's declared % concentration: "contains Syn-Ake" without a stated % likely delivers sub-therapeutic dose.

How to Use Syn-Ake

  1. 1
    Cleanse your face and pat completely dry

    Syn-Ake absorbs better through dry skin than damp skin.

  2. 2
    Step 2

    Dispense a pea-sized amount of 4% Syn-Ake serum onto your fingertip. If using a DIY formulation, confirm your concentration is at least 3 to 4%.

  3. 3
    Step 3

    Apply in thin layers to expression-line-prone areas: forehead (frontalis), crow's feet (periorbital region), frown lines (glabella), and around the mouth (perioral area). Use gentle pressing motions rather than rubbing.

  4. 4
    Step 4

    Wait 2 to 3 minutes for full absorption before layering other products. The peptide needs direct skin contact time.

  5. 5
    Follow with moisturizer and SPF in the morning

    In the evening, follow with your standard PM routine (niacinamide, hyaluronic acid, or facial oil are all compatible).

  6. 6
    Step 6

    Apply twice daily (AM and PM) for at least 4 weeks before assessing results. Full evaluation requires 12 weeks.

  7. 7
    If stacking with SNAP-8: apply both in the same step

    Either use a combined 4% Syn-Ake plus 10% SNAP-8 serum, or layer one immediately after the other before the absorption wait.

  8. 8
    Step 8

    Do not apply over freshly botulinum-toxin-injected areas, broken skin, active sunburn, or within 48 to 72 hours of a chemical peel (glycolic acid above 20% or TCA).

  9. 9
    Step 9

    Store opened serums at 2 to 8 degrees Celsius, protected from direct light. Stable at pH 5 to 7. Discard after 6 months.

Alternative Routes

Standard topical serum/cream (4% w/v)

N/A: this is the reference route and concentration

All manufacturer and clinical studies used topical emulsion or cream at 4% concentration. Low MW (495.58 Da, below the 500 Da penetration threshold) enables passive transcorneal diffusion without lipid conjugation requirement.

Nanoemulsion-enhanced topical formulation

Much lower active concentration (0.012% in 2024 study vs. 4% standard) with potentially higher local bioavailability due to lipid nanocarrier bypassing aqueous diffusion limitation

PMC11053593 (Pharmaceutics 2024): water-in-oil nanoemulsion of Syn-Ake at 0.012% showed sebum reduction and pore-size benefits in human subjects: a different endpoint than wrinkle reduction. No commercial nanoemulsion Syn-Ake product widely available as of 2026. DIY nanoemulsion formulation requires specialized equipment and surfactant expertise.

Microneedle-assisted topical delivery

Standard 4% concentration applied immediately post-needling; theoretically higher dermal delivery efficiency via mechanically disrupted barrier, but no published bioavailability data

Community-derived practice: use 0.25–0.5mm dermaroller or microneedle pen on clean skin, then apply Syn-Ake serum while skin remains permeable. Do not exceed 0.5mm depth in delicate periorbital area. Allow 24 hours before layering other actives post-needling. Microneedling alone improves wrinkle appearance through mechanical stimulation: confounds Syn-Ake-specific benefit assessment.

Syn-Ake Stacking Protocols

Works With

Avoid

Botulinum toxin (Botox, Dysport): same facial treatment zone

Both work through neuromuscular blockade at the same facial muscles. Additive inhibition is theoretically possible. Clinical significance for topical Syn-Ake is likely minimal given <1% systemic absorption, but applying Syn-Ake over fresh injection sites risks unpredictable absorption through disrupted skin barrier. Consult injector before combining.

High-concentration chemical exfoliants at peel strength (glycolic >20%, TCA peels)

Compromised skin barrier post-peel alters Syn-Ake absorption unpredictably and may cause excessive irritation. Wait 48–72 hours after peel treatment before resuming application.

Application to broken, sunburned, or actively inflamed skin

Compromised barrier dramatically increases transdermal penetration beyond intended superficial local action. Avoid active dermatitis, eczema flares, open wounds, or sunburned skin at application sites.

Estimated Cost

Generic / Research
7% Syn®-Ake serum: $28.30 (0.25 oz) to $87.05 (1 oz). 4% Syn-Ake facial serum: ~$129/30 ml. HydroPeptide Syn-Ake-containing serum: ~$154.
Compounded
Raw CAS 823202-99-9: ~$210/200 mg (2026 listing). 200 mg makes approximately 40–80 g of 4% w/w serum (depending on excipients), or ~400 g of 1% serum. Comparison: Botox $300–600/area/session × 3–4 sessions/year = $900–2,400/area/year.

Pricing updated 2026-04-09

Syn-Ake Side Effects

The most important safety context for Syn-Ake is the gap between what's been studied and what's on the market. No long-term safety study beyond 12 weeks exists for this ingredient as a standalone compound. The total published human evidence comes from roughly 80 subjects across two studies, one of which (Trookman 2009)[1] tested a multi-ingredient formula.

That said, the adverse event profile across all available data is clean.

Clinical studies at 4% concentration report no significant adverse events. The EWG Skin Deep database rates dipeptide diaminobutyroyl benzylamide diacetate as low risk across all toxicity categories: cancer, allergies, immunotoxicity, developmental and reproductive toxicity. Gok and colleagues [2] confirmed a favorable cytotoxicity and genotoxicity profile in vitro.

Rare cases of mild, temporary skin irritation have been reported. Slight redness, tingling, or burning sensation at the application site can occur, particularly in people with sensitive skin or a compromised skin barrier. Allergic contact dermatitis is theoretically possible but has not surfaced at clinically meaningful rates.

Systemic side effects are not expected. Syn-Ake acts locally within the upper skin layers. At less than 1% systemic absorption, the peptide doesn't reach meaningful plasma concentrations. No published data reports systemic Cmax, AUC, or elimination half-life.

For people receiving botulinum toxin injections: both compounds target neuromuscular transmission in the same facial muscles. The clinical overlap is likely minimal given topical Syn-Ake's low systemic absorption. Still, inform your injector. Applying the peptide over freshly injected sites also risks unpredictable absorption through a disrupted barrier.

Contraindications: myasthenia gravis or other neuromuscular junction disorders (theoretical risk of worsening muscle weakness). Pregnancy and breastfeeding (zero safety data in these populations). Children under 18 (no data). Active skin infections, open wounds, or severe dermatitis at intended application sites.

Stop use and consult a dermatologist if persistent redness, contact dermatitis, or unusual skin reactions develop that don't resolve with dose reduction.

Common Issues & Solutions

No result after 4 weeks: Check declared % concentration: "contains Syn-Ake" without a stated % likely delivers sub-therapeutic dose. Effective threshold is 3–4%. Verify twice-daily application on dry (not damp) skin. Manufacturer's 52% result was measured at 4% over 28 days: lower concentrations show meaningfully reduced efficacy.

No result after 8 weeks: Classify as non-responder at current concentration and product. Switch to a verified 4%+ product; a finished 7% serum is the usual benchmark. Or step up to the 4% Syn-Ake + 10% SNAP-8 dual-mechanism stack before concluding non-response to the peptide class.

Skin irritation or redness at application site: Reduce to once daily (PM only) for 2 weeks. If resolved, resume twice daily. If persists, patch-test individual serum components: reaction may be from the vehicle (phenoxyethanol, propanediol, fragrance) rather than the Syn-Ake peptide itself.

Effects disappeared after stopping: Expected and consistent with the reversible competitive binding mechanism. Muscle contraction returns to normal within 1–2 weeks as Syn-Ake dissociates from the mnAChR. Resume BID protocol: efficacy typically returns within 1–2 weeks of restarting.

Irritation when applying alongside retinol or vitamin C: Apply Syn-Ake and retinol at separate steps or separate AM/PM. Never apply immediately after a strong acid exfoliant: high-strength retinoids and peels acutely compromise barrier permeability, increasing irritation risk when multiple actives are layered.

Ask AI about this page

Ask AI for a second opinion on Syn-Ake dosing and side effects

Contraindications

  • Known allergy or hypersensitivity to dipeptide diaminobutyroyl benzylamide diacetate or any component amino acid
  • Active skin infections, open wounds, or severe dermatitis at intended application sites
  • Myasthenia gravis or other neuromuscular junction disorders (theoretical risk of exacerbating muscle weakness)
  • Concurrent use of botulinum toxin injections in the same area (additive neuromuscular blockade, consult physician)
  • Pregnancy or breastfeeding (no safety data available for this population)
  • Children under 18 (insufficient safety data)

Drug Interactions

  • Botulinum toxin injections (Botox, Dysport): potential additive neuromuscular relaxation when applied to the same facial area; consult dermatologist before combining
  • SNAP-8 (Acetyl Octapeptide-3): complementary mechanism (presynaptic SNARE inhibition vs. postsynaptic receptor blockade); combination is commonly used and generally well-tolerated
  • Topical retinoids (tretinoin, adapalene): may increase transient skin sensitivity when layered simultaneously; apply at separate times of day
  • High-concentration chemical peels (glycolic acid >20%, TCA peels): compromised skin barrier after peeling may alter peptide absorption; wait 48-72 hours post-peel before resuming
  • Aminoglycoside antibiotics: theoretical concern as aminoglycosides can potentiate neuromuscular blockade; clinical significance for topical peptide is likely negligible
  • Botulinum toxin (Botox, Dysport): same facial treatment zone
  • Compromised skin barrier post-peel alters Syn-Ake absorption unpredictably and may cause excessive irritation. Wait 48–72 hours after peel treatment before resuming application.

Product Quality

Recommended Monitoring

TestWhenTarget
Baseline + 4-week photography (expression lines)Week 0 and Week 4Visible reduction in expression line depth or roughness in consistent lighting conditions
Skin tolerance self-assessmentDays 3, 7, and 14 of initial useNot listed
Baseline + 4-week photography (expression lines)

Objective before/after comparison to detect responder status early. Expression wrinkles are highly subject to lighting and facial position bias without standardized photography.

Skin tolerance self-assessment

Contact dermatitis or irritant reaction identification. Most reactions present within the first 2 weeks. Allows switching to every-other-day protocol or isolating the vehicle ingredient as the sensitizer.

Syn-Ake Before and After

Minutes to hours

Subtle smoothing may be noticed immediately after application due to serum vehicle hydration. In vitro data shows 36% muscle contraction reduction within 1 minute and 82% within 2 hours, though topical onset in vivo is slower due to skin penetration time.

Week 1-2

Peptide begins accumulating in the upper skin layers with twice-daily application. Some users report a softening of fine surface expression lines. Full neuromuscular effects are building as steady-state skin concentrations are approached.

Weeks 2-4

Measurable wrinkle reduction becomes apparent. The manufacturer 28-day study reported up to 52% improvement in forehead wrinkle depth at this timepoint. Expression lines around the eyes and mouth begin to visibly soften.

Weeks 4-12

Continued improvement in wrinkle depth and skin smoothness. Clinical studies show sustained significant results (p <= 0.0003) through month 3. Deeper expression lines show gradual improvement as sustained muscle relaxation allows the skin to recover from chronic mechanical creasing.

After stopping

Effects are not permanent. Because Syn-Ake works through reversible receptor binding, muscle contraction returns to normal within 1-2 weeks after discontinuation. Wrinkle depth gradually returns toward baseline as facial muscles resume habitual expression patterns.

What to Expect

Minutes to hours after your first application: don't expect visible wrinkle change. Any immediate smoothing you notice comes from the serum vehicle (usually hyaluronic acid), not the peptide itself. In lab conditions, cultured muscle cells show 36% contraction reduction at one minute and 82% at two hours, but topical delivery through intact skin is slower.

Weeks 1 to 2: the peptide accumulates in your upper skin layers with twice-daily application. Its molecular weight (495.58 Da) allows passive diffusion through the stratum corneum. Some users report a subtle softening of fine lines, though this is hard to separate from vehicle hydration at this stage.

Weeks 2 to 4: this is where measurable change starts. The manufacturer's 28-day endpoint found up to 52% wrinkle depth reduction in 45 subjects using 4% cream. Community consensus calls this the "you can tell it's doing something" window. If you're a responder, forehead lines and crow's feet start visibly softening. Non-responders see minimal change.

Weeks 4 to 12: improvement continues and plateaus around week 6 to 8 for most users. Trookman 2009 (multi-ingredient formulation)[1] confirmed statistically significant wrinkle reduction at every 4-week interval through month 3 (p less than 0.0003). Deeper expression lines improve gradually as sustained muscle relaxation reduces chronic mechanical creasing. Many users shift to once-daily maintenance at this stage.

After stopping: effects are not permanent. Syn-Ake binds the acetylcholine receptor reversibly, so muscle contraction returns to normal within one to two weeks. Wrinkle depth returns toward your pre-treatment baseline as habitual expression patterns resume. No rebound worsening has been reported. You can restart the protocol at any point without loss of efficacy.

Detailed Timeline: Science vs Community

Minutes to hours (first application)
Science

In vitro: 36% muscle contraction reduction within 1 minute, 82% within 2 hours at 0.025% (cultured muscle cells). Topical in vivo onset is slower due to skin penetration kinetics. Peptide begins accumulating in the stratum corneum.

Community

Some immediate plumping or smoothing sensation attributable to HA serum vehicle hydration, not the peptide. No visible wrinkle reduction expected on first application.

Weeks 1–2
Science

Peptide accumulates toward steady-state concentration in upper skin layers with BID application. Low MW (495.58 Da) enables passive transcorneal diffusion. No measurable clinical wrinkle change at this stage.

Community

Subtle softening of fine surface lines occasionally reported; primarily attributed to vehicle hydration and expectation effects. Distinct wrinkle improvement not yet expected.

Weeks 2–4
Science

Manufacturer's primary endpoint: up to 52% wrinkle depth reduction at day 28 in 45 subjects applying 4% forehead cream. Best available human data for single-compound assessment (manufacturer-funded, not peer-reviewed).

Community

Visible softening of forehead lines and crow's feet in responders. Community commonly identifies this as the "you can tell it's doing something" timepoint. Non-responders see minimal change.

Weeks 4–12
Science

Trookman 2009 (multi-ingredient, confounded): statistically significant wrinkle reduction at all 4-week intervals through month 3 (p≤0.0003). Deeper expression lines show gradual improvement as sustained muscle relaxation reduces chronic mechanical creasing of overlying skin.

Community

Continued improvement that plateaus after week 6–8. Many users adopt maintenance frequency (once daily PM). Skin texture improvement reported beyond wrinkle depth reduction alone.

After stopping
Science

Reversible competitive receptor binding: muscle contraction returns to normal as Syn-Ake dissociates from mnAChR epsilon subunit. Wrinkle depth returns toward pre-treatment baseline as habitual expression patterns resume. No permanent structural benefit documented.

Community

Consistent with science: lines reappear within 1–2 weeks of stopping. No rebound worsening. Users can restart protocol without loss of efficacy.

Pharmacokinetics

Half-Life
N/A
Bioavailability
Topical: <1% systemic absorption; local skin penetration enabled by MW < 500 Da
Tmax
Not applicable (topical, non-systemic). In vitro muscle relaxation onset within 1-2 minutes; peak effect at ~2 hours.
Data Confidence
low

Source: No systemic pharmacokinetic data available. Syn-Ake is a topical cosmeceutical peptide with a molecular weight of 495.58 Da that acts locally within the skin. Its small size enables stratum corneum penetration but no published studies report systemic Cmax, AUC, or elimination half-life. The peptide exerts its effects through local receptor binding in the upper dermal layers without significant systemic absorption.

Molecular Profile

Amino Acids
3
Sequence
APK
HydrophobicPolarPositiveNegativeSpecialHow we generate these icons
Identifiers
CAS: 823202-99-9

Who Should Consider Syn-Ake

  • Adults over 30 seeking to reduce expression lines and dynamic wrinkles without injections
  • Individuals looking for a topical botox-like alternative for forehead and crow's feet lines
  • Skincare enthusiasts building multi-peptide anti-aging protocols targeting neuromuscular relaxation
  • People with moderate expression lines who want to delay or supplement botulinum toxin treatments
  • Those seeking a non-invasive, reversible approach to facial muscle relaxation for wrinkle prevention

Related Peptides

What Changed for Syn-Ake

No material change since Oct 5, 2026. Checked against Federal Register, openFDA Drugs@FDA, openFDA drug labels, openFDA enforcement reports and PubMed retraction links on Oct 14, 2026. How the change record works

Peptide Schedule Research TeamReviewed Apr 7, 20267 Citations

References

  1. [1]Immediate and Long-term Clinical Benefits of a Topical Treatment for Facial Lines and Wrinkles (J Clin Aesthet Dermatol 2009) (opens in a new tab)PubMed (opens in a new tab)PubMed
  2. [2]Anti-aging Activity of Syn-Ake Peptide by In Silico Approaches and In Vitro Tests (J Biomol Struct Dyn 2024) (opens in a new tab)PubMed (opens in a new tab)PubMed

Related Tools

Storage & Stability

Before Reconstitution
Store dry powder at -20°C for long-term stability, or 2-8°C for up to 12 months. Protect from light and moisture.
After Reconstitution
Topical serums should be stored at 2-8°C away from direct light. Use within 6 months after opening.
Temperature
0-4°C (32-39°F) for raw ingredient; room temperature acceptable for sealed commercial products with preservative systems

Frequently Asked Questions

Syn-Ake is a fully synthetic tripeptide designed in a computer to mimic Waglerin-1 from Temple Pit Viper venom. No actual venom is used in production. It's synthesized chemically (CAS 823202-99-9) by DSM-Firmenich and is vegan-compatible. The "snake venom" label is marketing for the mechanism of action.

They hit the neuromuscular junction at different sites. Syn-Ake binds postsynaptically to the acetylcholine receptor, blocking the muscle from receiving the contraction signal. SNAP-8 works presynaptically, preventing acetylcholine release in the first place. They're complementary: 4% Syn-Ake + 10% SNAP-8 is a common DIY formulation.

Here's the thing: the most-cited study (Trookman 2009, PMID 20729942) was funded by SkinMedica, had two SkinMedica employee-authors, and tested a multi-ingredient formulation with growth factors, other peptides, hyaluronic acid, and antioxidants. Wrinkle reduction can't be attributed to Syn-Ake alone. The most independent evidence is a 2024 nanoemulsion study (PMC11053593) that found sebum/pore benefits at 0.012%: a different endpoint entirely.

Too early. The manufacturer's own 52% reduction figure was measured at 28 days. The Trookman study endpoint was 3 months. Topical peptides need time to build steady-state concentration in the upper dermal layers. Expect meaningful changes at 4 weeks with continued improvement through 12 weeks. Also check your product concentration: below 3% reduces efficacy significantly.

Use caution and tell your injector. Both work through neuromuscular blockade on the same facial muscles, so additive inhibition is theoretically possible. The clinical significance is likely minimal given less than 1% systemic absorption from topical Syn-Ake. Most dermatologists won't object, but informing your physician is the right call.